Skip to content
Catalyst

PapersPMID:35889747

Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile.

Nutrients2022The record ↗

  1. Finding, moderate evidencelowersInterleukin-6 concentration

What moved

1 findingHow to read these marks →
  • “After normalization with baseline, Figure 4B shows a significant decrease in serum IL-6 level at 1, 3, and 6 months of low- and standard-dose Arthrospira consumption (* p < 0.05, ** p < 0.01, *** p < 0.001, compared to control).”
    Study
    RCT
    Interests
    Industry funded
    Dose studied
    3 g daily or 6 g daily as add-on to nucleos(t)ide analogue, 6 months
    Population
    Adults aged 20 to 75 with chronic hepatitis B on nucleos(t)ide analogues for at least one year with undetectable HBV DNA; nucleos(t)ide analogue continued in all arms (background); 60 randomised to control, 3 g/day or 6 g/day Arthrospira, 56 retained; low and standard dose groups reported together against control

Study record

Design
randomised controlled trial
Species
human / mixed
Population
Chronic hepatitis B patients receiving nucleos(t)ide analogue for at least one year with undetectable HBV DNA
Participants
60
Comparator
no treatment
Duration
183 days
Endpoints measured
30